Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 3
2005 8
2006 7
2007 9
2008 3
2009 5
2010 4
2011 7
2012 12
2013 5
2014 7
2015 7
2016 10
2017 7
2018 13
2019 10
2020 17
2021 6
2022 8
2023 6
2024 3
2025 8
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

149 results

Results by year

Filters applied: . Clear all
Page 1
Antibody-drug conjugates for cancer therapy.
Thomas A, Teicher BA, Hassan R. Thomas A, et al. Among authors: hassan r. Lancet Oncol. 2016 Jun;17(6):e254-e262. doi: 10.1016/S1470-2045(16)30030-4. Lancet Oncol. 2016. PMID: 27299281 Free PMC article. Review.
Treatment of Pleural Mesothelioma: ASCO Guideline Update.
Kindler HL, Ismaila N, Bazhenova L, Chu Q, Churpek JE, Dagogo-Jack I, Bryan DS, Drazer MW, Forde P, Husain AN, Sauter JL, Rusch V, Bradbury PA, Cho BCJ, de Perrot M, Ghafoor A, Graham DL, Khorshid O, Lebensohn A, White J, Hassan R. Kindler HL, et al. Among authors: hassan r. J Clin Oncol. 2025 Mar 10;43(8):1006-1038. doi: 10.1200/JCO-24-02425. Epub 2025 Jan 8. J Clin Oncol. 2025. PMID: 39778125
Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma.
Mansfield AS, Vivien Yin J, Bradbury P, Kwiatkowski DJ, Patel S, Bazhenova LA, Forde P, Lou Y, Dizona P, Villaruz LC, Arnold SM, Khalil M, Kindler HL, Koczywas M, Pacheco J, Rolfo C, Xia B, Mikula E, Chen L, Patel K, Smith KER, Cao L, Shapiro G, Costello BA, Adjei A, Sharon E, Moscow JA, Zamboni W, Hassan R. Mansfield AS, et al. Among authors: hassan r. Lung Cancer. 2024 Sep;195:107928. doi: 10.1016/j.lungcan.2024.107928. Epub 2024 Aug 13. Lung Cancer. 2024. PMID: 39197359 Free PMC article. Clinical Trial.
Advances in anticancer immunotoxin therapy.
Alewine C, Hassan R, Pastan I. Alewine C, et al. Among authors: hassan r. Oncologist. 2015 Feb;20(2):176-85. doi: 10.1634/theoncologist.2014-0358. Epub 2015 Jan 5. Oncologist. 2015. PMID: 25561510 Free PMC article. Review.
Farletuzumab in lung cancer.
Thomas A, Maltzman J, Hassan R. Thomas A, et al. Among authors: hassan r. Lung Cancer. 2013 Apr;80(1):15-8. doi: 10.1016/j.lungcan.2012.12.021. Epub 2013 Jan 26. Lung Cancer. 2013. PMID: 23357463 Free PMC article. Review.
Mesothelin targeted cancer immunotherapy.
Hassan R, Ho M. Hassan R, et al. Eur J Cancer. 2008 Jan;44(1):46-53. doi: 10.1016/j.ejca.2007.08.028. Epub 2007 Oct 22. Eur J Cancer. 2008. PMID: 17945478 Free PMC article. Review.
Immunotoxin therapy of cancer.
Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ. Pastan I, et al. Among authors: hassan r. Nat Rev Cancer. 2006 Jul;6(7):559-65. doi: 10.1038/nrc1891. Nat Rev Cancer. 2006. PMID: 16794638 Review.
Orbital metastases from malignant mesothelioma.
Mian I, Padiernos E, Hassan R, Ghafoor A. Mian I, et al. Among authors: hassan r. Lancet Oncol. 2020 Feb;21(2):e117. doi: 10.1016/S1470-2045(19)30822-8. Lancet Oncol. 2020. PMID: 32007197 Free PMC article. No abstract available.
Treatment of Pleural Mesothelioma: ASCO Guideline Clinical Insights.
Kindler HL, Dagogo-Jack I, de Perrot M, Drazer MW, Ismaila N, Hassan R. Kindler HL, et al. Among authors: hassan r. JCO Oncol Pract. 2025 Oct;21(10):1413-1416. doi: 10.1200/OP-25-00035. Epub 2025 Mar 7. JCO Oncol Pract. 2025. PMID: 40053896 No abstract available.
149 results